These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8791124)

  • 1. Cost-effectiveness considerations in chemoprevention of cancer.
    Habbema JD; van der Heide A; van den Bosch JM; Bonneux L
    IARC Sci Publ; 1996; (136):131-8. PubMed ID: 8791124
    [No Abstract]   [Full Text] [Related]  

  • 2. Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.
    Kondo M; Hoshi SL; Toi M
    Jpn J Clin Oncol; 2009 Nov; 39(11):767-70. PubMed ID: 19656807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Despite positive studies, popularity of chemoprevention drugs increasing slowly.
    Zielinski SL
    J Natl Cancer Inst; 2004 Oct; 96(19):1410-2. PubMed ID: 15467023
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
    Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
    Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemoprevention of cancer. Prevention of cancer in groups with increased risk].
    Sanner T; Dybing E
    Tidsskr Nor Laegeforen; 1996 Aug; 116(19):2329-33. PubMed ID: 8804210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoprevention clinical trials: it is time to turn success into progress.
    Brown PH
    Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1531-2. PubMed ID: 17684123
    [No Abstract]   [Full Text] [Related]  

  • 7. [Chemoprevention of prostate cancer].
    Xie LP; Qin J
    Zhonghua Nan Ke Xue; 2005 Apr; 11(4):243-6. PubMed ID: 15921250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer.
    Lee YC; Lin JT; Wu HM; Liu TY; Yen MF; Chiu HM; Wang HP; Wu MS; Hsiu-Hsi Chen T
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):875-85. PubMed ID: 17507609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why chemoprevention?
    Hakama M
    IARC Sci Publ; 1996; (136):1-5. PubMed ID: 8791109
    [No Abstract]   [Full Text] [Related]  

  • 10. Cancer chemoprevention with dietary phytochemicals.
    Surh YJ
    Nat Rev Cancer; 2003 Oct; 3(10):768-80. PubMed ID: 14570043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut check: can cost-effectiveness analysis help eliminate gastric cancer in Asia?
    Ramsey S
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):873-4. PubMed ID: 17507608
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemoprevention of oesophageal cancer.
    Muñoz N; Buiatti E
    IARC Sci Publ; 1996; (136):27-33. PubMed ID: 8791112
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioural intervention versus chemoprevention.
    Henderson M; Thompson B; Kristal A
    IARC Sci Publ; 1996; (136):123-30. PubMed ID: 8791123
    [No Abstract]   [Full Text] [Related]  

  • 15. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II.
    Moyad MA
    Urol Oncol; 2004; 22(6):472-7. PubMed ID: 15610864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I.
    Moyad MA
    Urol Oncol; 2004; 22(6):466-71. PubMed ID: 15610863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost of prostate cancer chemoprevention: a decision analysis model.
    Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
    Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1485-9. PubMed ID: 16896037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer chemoprevention: a summary of the current evidence.
    Bonovas S; Tsantes A; Drosos T; Sitaras NM
    Anticancer Res; 2008; 28(3B):1857-66. PubMed ID: 18630472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethical issues of intervention trials in cancer.
    Sancho-Garnier H; Joseph R
    IARC Sci Publ; 1996; (136):121-2. PubMed ID: 8791122
    [No Abstract]   [Full Text] [Related]  

  • 20. Cancer chemoprevention: how do we know what works?
    Neugut AI; Lebwohl B; Hershman DL
    J Clin Oncol; 2007 Apr; 25(12):1461-2. PubMed ID: 17442987
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.